Clinilabs
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Chronic Obstructive Pulmonary Disease (COPD).
This is Clinilabs’ third clinical trial examining drug effects in patients with COPD. “As a specialty CRO, it is exciting to grow our franchise in respiratory disorders as we expand our expertise to an ever wider range of conditions” states Barbara Smallwood, Vice President of Business Development at Clinilabs.
Enrollment for this study is expected to begin in April 2011.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.